Hook - Thesis
Erasca just delivered a one-two clinical and strategic punch that, in our view, warrants an active long trade. On 11/20/2026 the company reported broad Phase 1 efficacy for ERAS-0015 and highlighted promising early activity for ERAS-4001. That release was immediately preceded by a clinical collaboration with Bristol-Myers Squibb announced on 11/17/2026 to test ERAS-0015 together with BMS’s PRMT5 inhibitor navlimetostat in MTAP-deleted pancreatic cancer. Those two items change the risk calculus: ERAS-0015's robust response rates and a BMS-sponsored study both shorten execution risk and create multiple binary re-rating opportunities.
Why the market should care
Erasca is a clinical-stage precision oncology company focused on RAS/MAPK-driven cancers. The market cares because successful targeting of RAS - and specifically KRAS - has been one of oncology’s toughest but highest-value problems. ERAS-0015 is a pan-RAS molecular glue showing what management calls "broad and robust" responses in Phase 1. That alone can lift valuation probabilities; pairing that agent in a BMS-sponsored trial for MTAP-deleted pancreatic cancer both brings a blue-chip collaborator and outsources sponsor risk for the combination study. Put another way: the company is seeing academic-grade biology convert into clinically meaningful responses while simultaneously shortening the path to a pivotal program in high-unmet-need indications.
Concrete data points that matter
- Market capitalization sits in the neighborhood of $4.76 billion and enterprise value is approximately $4.87 billion.
- Recent filings show negative free cash flow of roughly $109.24 million, underscoring the company is still burning cash to advance trials.
- The company reports a cash figure that implies roughly $948 million on a per-share basis when combined with the ~351 million shares outstanding - a significant liquidity cushion for near-term trial execution.
- Short interest is material; the most recent settled short interest figure was ~37.2 million shares, translating into multi-day cover dynamics that can amplify moves on positive news.
How I think this unfolds
ERAS-0015’s Phase 1 data (11/20/2026) showed high objective response rates in hard-to-treat cohorts and a favorable safety profile. Management has signaled intentions to start potentially registration-enabling lung cancer trials and an accelerated Phase 3 in pancreatic cancer in H1 2027. Those program starts - particularly a registrational path in pancreatic cancer - are the core value drivers. The BMS collaboration (11/17/2026) is targeted at MTAP-deleted pancreatic tumors and will be sponsored by BMS, which materially lowers the company’s near-term cash burden for that particular combination while improving the odds of successful enrollment and execution.
Valuation framing
On a headline basis Erasca trades at roughly a mid-single-digit billion dollar market cap despite negative earnings and meaningful FCF burn. That suggests the market is already pricing some value into the pipeline. The proper way to think about valuation here is probabilistically and catalyst-driven: the stock needs a sequence of successful clinical readouts and trial initiations to justify a material multiple expansion. The company’s enterprise value of ~$4.87 billion versus an implied cash asset near $948 million means the EV attributable to the pipeline/execution sits around $3.9 billion. That is a high bar for a pre-revenue biotech, which is why risk management (explicit stops, position sizing) is essential for any trade.
Catalysts to watch (near and medium-term)
- Initiation of registration-enabling lung cancer trial for ERAS-0015 - expected H1 2027.
- Start of accelerated Phase 3 trial in pancreatic cancer for ERAS-0015 - expected H1 2027.
- Data readouts from early combination cohorts (chemotherapy and immunotherapy) for ERAS-0015, continuous through 2027.
- Updates on ERAS-4001’s early clinical activity and safety profile - incremental slides and case studies can move the tape.
- Enrollment and early safety/PK updates from the BMS-sponsored navlimetostat combination trial in MTAP-deleted pancreatic cancer.
Trade plan - actionable and explicit
We are recommending an aggressive buy with clearly defined risk limits. This is a high-volatility biotech trade designed for traders who can stomach clinical binary outcomes.
| Entry | Target | Stop | Horizon |
|---|---|---|---|
| $13.60 | $22.00 | $9.50 | Long term (180 trading days) |
Why these levels? Entry at $13.60 is close to the current trading level and gives participation in early clinical momentum without chasing into a sharp intraday pop. The $22 target is premised on a partial de-risking and re-rating following either an initiation of a registration-enabling program with supportive Phase 1 data or positive early combination signals from the BMS study. The stop at $9.50 limits downside in a name with substantial binary risk and protects capital in case of trial setbacks, adverse regulatory noise, or continued legal overhangs.
Horizon and trade management
This trade is intended to be held for the long term (180 trading days). The rationale: multiple registration-enabling moves and combination study milestones are concentrated over the next 6-9 months. For traders who prefer staged exposure, consider reducing size after a 30-50% move higher and re-entering on setbacks, but keep stops in place. For shorter-term traders, set expectations for higher intraday volatility driven by short-covering and news flow; a short-term (10 trading days) play could capture a headline pop but carries outsized risk if you’re not ready to hold through clinical updates. A mid-term (45 trading days) holder should focus on early BMS combination updates or any incremental ERAS-4001 activity releases.
Risks and counterarguments
- Clinical execution risk: Early Phase 1 data are encouraging, but later-stage trials can fail to replicate response rates or may reveal safety issues when broader populations are exposed.
- Regulatory and enrollment risk: The company plans registration-enabling and accelerated Phase 3 programs in H1 2027; delays, enrollment challenges, or regulatory feedback could push timelines and pressure the stock.
- Legal and governance overhang: Multiple shareholder investigations and prior leadership turnover have created litigation and governance headlines that could sap investor confidence and increase volatility around any news events.
- Competition and IP risk: Rivals are also chasing RAS-directed therapies. Patent disputes or competing agents with superior efficacy/safety could blunt Erasca’s commercial prospects.
- Balance sheet and dilution risk: The company is burning cash (negative free cash flow of ~-$109.24M) and may need to raise capital, diluting current shareholders unless partnerships like the BMS collaboration offset near-term funding needs.
- Market microstructure risk: Elevated short interest and high short-volume days mean the stock can gap materially in either direction on news or liquidity changes.
Counterargument to the bullish thesis: One plausible bear case is that ERAS-0015’s Phase 1 signals represent a narrow subset effect and won’t scale in larger, more heterogeneous registrational cohorts. If subsequent cohorts show lower response rates or tolerability issues emerge in combination regimens, the pipeline’s valuation premium could evaporate quickly. Legal or patent challenges from competitors could also force management to divert resources to defense rather than development, further slowing progress.
What would change my mind
I would materially reduce the rating or flip to neutral/short if any of the following occur: a) registrational trial initiations are delayed beyond mid-2027 without a clear mitigation plan, b) safety signals emerge in combination cohorts that constrain dosing or patient eligibility, c) material negative rulings in litigation or credible patent claims that jeopardize core assets, or d) unexplained cash depletion forcing dilutive financing before the company secures additional non-dilutive funding or partnering that meaningfully covers trial budgets.
Conclusion
Erasca now sits in an interesting spot: encouraging early clinical data for ERAS-0015, suggestive activity for ERAS-4001, and a BMS collaboration that reduces sponsor risk and validates the biology. For traders comfortable with biotech binary risk, we recommend a long trade executed with tight risk controls: entry at $13.60, a stop at $9.50, and a target of $22.00 across a long-term horizon (180 trading days). The path to that target is clear - pipeline de-risking via trial initiations and positive combination data - but so is the downside: regulatory setbacks, legal overhang and clinical disappointments. Position sizing and explicit stops are essential in this high-volatility name.